Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine, quadrivalent
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal conjugate vaccine, quadrivalent is an active immunizing agent used to prevent infection caused by Neisseria meningitidis serogroups A, C, W, and Y. The vaccine works by stimulating the body to produce antibodies against these specific serogroups of meningococcal bacteria. It does not protect against serogroup B meningococcal disease. The vaccine helps prevent meningococcal meningitis (infection of the brain and spinal cord) and meningococcemia (infection of the blood), which can be life-threatening or cause serious long-term disabilities.
- Brand names
- MenactraMenQuadfiMenveo
- Other names
- MenACWYmeningococcal vaccine, tetanus toxoid conjugate quadrivalent
Beyond the preview
Go deeper on meningococcal conjugate vaccine, quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine, quadrivalent.